R., Bathelt, C., Baur, F., Caviezel, B., Vukajlovic, T., Fischer, M., & Winzeler, B
Sip on clear fluids, such as water, herbal tea, or broth, throughout the day
GLP-1 Receptor Agonist Market Opportunities: Expanded cardiovascular indications and biosimilar development creating transformative GLP-1 receptor agonist market opportunities The cardiovascular indication expansion following SELECT trial approval for semaglutide in cardiovascular risk reduction in obese non-diabetic patients is qualitatively important because it changes who prescribes GLP-1 drugs
This understanding has led to the development of targeted nutritional supplements that support both digestive wellness and hormonal balance
At IAPAM, we continue to follow developments in GLP-1 weight loss training and education, helping physicians navigate the rapidly evolving landscape of obesity medicine and understand the complex reimbursement policies that affect their practices